Segment Disclosures (Tables)

3 Months Ended

Sep. 30, 2024

Summary of segment data for sales, cost of sales and gross margin

Segment data for sales, cost of sales and gross margin for the three and nine months ended September 30, 2024 and 2023 are presented in the table below.



	Ammonia		Granular Urea(1)		UAN(1)		AN(1)		Other(1)		Consolidated
	(in millions)
Three months ended September 30, 2024
Net sales	$	353	$	388	$	406	$	106	$	117	$	1,370
Cost of sales	270		228		272		82		74		926
Gross margin	$	83	$	160	$	134	$	24	$	43	444
Total other operating costs and expenses											82
Equity in earnings of operating affiliate											2
Operating earnings											$	364
Three months ended September 30, 2023
Net sales	$	235	$	360	$	435	$	114	$	129	$	1,273
Cost of sales	214		226		302		79		75		896
Gross margin	$	21	$	134	$	133	$	35	$	54	377
Total other operating costs and expenses											97
Equity in losses of operating affiliate(2)											(36)
Operating earnings											$	244

Nine months ended September 30, 2024
Net sales	$	1,164	$	1,252	$	1,306	$	318	$	372	$	4,412
Cost of sales	869		711		813		262		225		2,880
Gross margin	$	295	$	541	$	493	$	56	$	147	1,532
Total other operating costs and expenses											228
Equity in earnings of operating affiliate											1
Operating earnings											$	1,305
Nine months ended September 30, 2023
Net sales	$	1,184	$	1,431	$	1,650	$	377	$	418	$	5,060
Cost of sales	797		775		937		264		243		3,016
Gross margin	$	387	$	656	$	713	$	113	$	175	2,044
Total other operating costs and expenses											228

Equity in losses of operating affiliate(2)											(12)
Operating earnings											$	1,804

_______________________________________________________________________________

(1)The cost of the products that are upgraded into other products is transferred at cost into the upgraded product results.

(2)Equity in losses of operating affiliate for the three and nine months ended September 30, 2023 includes an impairment of our equity method investment in PLNL of $43 million. See Note 8—Equity Method Investment for additional information.